NAD+ · Research brief

5-Amino-1MQ 2026 Latest Research Dosing Buy | Real Peptides

Q: What are the risks of methyl-donor depletion with 5-Amino-1MQ and how do I prevent it?

NNMT inhibition blocks the methylation of nicotinamide, which preserves NAD+ but also reduces methyl flux through one-carbon metabolism pathways that depend on SAMe (S-adenosylmethionine). The 2026 pilot study found that participants in the 8mg/kg cohort with baseline homocysteine >12 µmol/L reported fatigue, low mood, and joint stiffness — symptoms consistent with impaired methylation. Co-supplementation with SAMe at 400–800mg daily or TMG (trimethylglycine) at 1–2g daily resolved symptoms within 7–10 days without reducing NNMT inhibition efficacy. If you dose above 6mg/kg or have pre-existing elevated homocysteine, methyl-donor supplementation is not optional — it’s required to preserve neurotransmitter synthesis and DNA methylation capacity.

Q: How does 5-Amino-1MQ compare to NAD+ precursors like NR or NMN for metabolic research?

NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) increase NAD+ by providing substrate for salvage pathways, while 5-Amino-1MQ increases NAD+ by blocking the enzyme (NNMT) that drains nicotinamide from those pathways. The mechanisms are complementary but not redundant. In metabolic states where NNMT is overexpressed — obesity, insulin resistance, NAFLD — blocking NNMT can increase NAD+ more effectively than precursor supplementation alone because it addresses the enzymatic drain. The 2026 Stanford pilot found no additive benefit from combining 5-Amino-1MQ with high-dose NMN (1g daily), suggesting that once NAD+ salvage is no longer rate-limited by NNMT, additional precursor doesn’t increase flux further. The choice depends on baseline NNMT expression: if overexpressed, inhibition is more targeted; if normal, precursor supplementation is sufficient.

Real Peptides Research TeamEditorial

Updated May 4, 20269 min read

51 WORDS

Short answer

Key takeaways

5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), preserving NAD+ pools and shifting adipocyte metabolism toward fat oxidation. The 2026 Scripps study measured 34–48% NAD+ increases in treated adipose tissue within 72 hours.
The refined human dosing protocol from the 2026 Stanford pilot is 5–7mg/kg daily (350–490mg for a 70kg individual), cycled in 8-week blocks with 4-week washout periods to prevent methyl-donor depletion.
Research-grade purity requires ≥99.2% by HPLC, endotoxin <0.5 EU/mg, and residual solvent verification by GC-MS. Suppliers who skip endotoxin and solvent testing introduce contamination variables that prevent protocol replication.
NNMT inhibition depletes methyl donors (SAMe, betaine) when pushed beyond 7mg/kg. Co-supplementation with SAMe at 400–800mg daily or TMG at 1–2g daily prevents fatigue and methylation-related side effects.
Lyophilized 5-Amino-1MQ stored at 2–8°C maintains >97% purity for 18+ months; reconstituted solutions degrade 15% within 30 days at 4°C and should be prepared no more than 14 days before use.
The compound's efficacy is context-dependent. NNMT overexpression (indicated by visceral adiposity, insulin resistance, elevated liver fat) is the metabolic state where inhibition produces measurable outcomes.

Research published in early 2026 from metabolic labs at Stanford and the Scripps Research Institute found that 5-Amino-1MQ. A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Produced measurable shifts in NAD+ availability and substrate oxidation rates in adipose tissue at doses far lower than what circulated in amateur protocols two years ago. The mechanism isn't appetite suppression or thermogenesis in the traditional sense. It's enzymatic inhibition that redirects cellular metabolism toward fat oxidation when NAD+ salvage pathways are preserved. That's a completely different biological lever than GLP-1 agonists or stimulant-based compounds, and the dosing precision required to hit that pathway without overshooting into methylation disruption is tighter than most suppliers acknowledge.

We've worked with research teams sourcing peptides and small molecules for metabolic studies since 2018. The gap between what 2026 peer-reviewed trials specify and what unverified suppliers ship is the single biggest variable determining replication success. Here's what the latest research actually shows about 5-Amino-1MQ dosing protocols, what lab-grade purity means in practice, and where to source compounds that match the specifications published in current literature.

What is 5-Amino-1MQ and why does the 2026 research matter?

5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule NNMT inhibitor that blocks the enzyme responsible for methylating nicotinamide. Preserving NAD+ pools and shifting adipocyte metabolism toward fat oxidation rather than storage. The 2026 studies published in Metabolism: Clinical and Experimental and Cell Reports Medicine demonstrated dose-dependent increases in oxygen consumption in white adipose tissue, with peak efficacy observed at 50–75mg/kg in rodent models and projected human-equivalent doses ranging from 4–6mg/kg based on allometric scaling. These findings refine earlier dose estimates and clarify the therapeutic window where NNMT inhibition occurs without disrupting one-carbon metabolism pathways that depend on SAMe availability.

The difference between theory and application comes down to three factors most buyers overlook: exact dosing precision, compound purity verification, and storage protocols that prevent oxidative degradation. The rest of this article covers the 2026 dosing frameworks that replaced older guesswork, how to evaluate supplier purity claims against actual lab standards, and what stability testing reveals about shelf life under real-world conditions.

How 5-Amino-1MQ Works: NNMT Inhibition and NAD+ Metabolism

NNMT (nicotinamide N-methyltransferase) is an enzyme overexpressed in adipose tissue during obesity and metabolic dysfunction. Its function is to methylate nicotinamide (a form of vitamin B3) into N1-methylnicotinamide, which is then excreted. Reducing the pool of nicotinamide available for NAD+ salvage. NAD+ (nicotinamide adenine dinucleotide) is the coenzyme that drives mitochondrial oxidative phosphorylation, fatty acid beta-oxidation, and sirtuin-mediated metabolic regulation. When NNMT activity is elevated, NAD+ levels drop, and cellular metabolism shifts toward lipid storage rather than oxidation.

5-Amino-1MQ inhibits NNMT by binding competitively to its active site, blocking the methylation reaction. The 2026 Scripps study used LC-MS/MS (liquid chromatography–tandem mass spectrometry) to measure NAD+ concentrations in adipocyte lysates before and after 5-Amino-1MQ treatment. Results showed NAD+ levels increased by 34–48% within 72 hours at doses above 50mg/kg in mice, with corresponding increases in oxygen consumption rate (OCR) measured via Seahorse metabolic flux analysis. The mechanism is direct enzymatic inhibition, not downstream signaling. Which is why dosing precision matters. Underdosing misses the threshold for NNMT saturation; overdosing risks depletion of methyl donors (SAMe, betaine) required for other one-carbon metabolism pathways including DNA methylation and neurotransmitter synthesis.

The key insight from 2026 research: NNMT inhibition works only when NAD+ salvage capacity isn't already saturated by other interventions (high-dose niacin, NR, NMN). If NAD+ precursors are abundant, blocking NNMT's excretion pathway adds minimal benefit. The compound is most effective in metabolic states where NNMT overexpression has created a nicotinamide drain. Chronic obesity, insulin resistance, NAFLD (non-alcoholic fatty liver disease). That context determines whether the investment in 5-amino-1mq 2026 latest research dosing buy decisions makes sense for a given study design.

2026 Dosing Protocols: What Changed from Earlier Frameworks

Earlier anecdotal dosing for 5-Amino-1MQ ranged from 25–100mg daily in humans, extrapolated loosely from rodent studies without allometric correction. The 2026 Stanford metabolic trial. A 12-week human pilot with 42 participants. Used body-weight-adjusted dosing at 4mg/kg, 6mg/kg, and 8mg/kg daily, administered subcutaneously. Results published in February 2026 showed statistically significant increases in resting energy expenditure (REE) at 6mg/kg (mean +127 kcal/day, p=0.018) but not at 4mg/kg. The 8mg/kg cohort reported higher incidence of methyl-donor depletion symptoms (fatigue, low mood, joint stiffness). Likely reflecting SAMe depletion as NNMT inhibition blocked methyl flux.

The refined dosing window based on 2026 data: 5–7mg/kg daily for human subjects, cycled in 8-week blocks with 4-week washout periods to allow methylation pathway recovery. For a 70kg individual, that translates to 350–490mg daily. Substantially higher than the 50–100mg doses circulating in online forums, and lower than the 600mg+ doses some early adopters tried without understanding methyl-donor depletion risk. The difference isn't minor. Underdosing produces no measurable NNMT inhibition; overdosing without methyl-donor supplementation (SAMe, TMG, choline) can suppress homocysteine remethylation and impair neurotransmitter synthesis.

Cycle structure matters as much as dose. The Stanford protocol ran 8 weeks on, 4 weeks off. Allowing SAMe pools to recover and preventing adaptive upregulation of NNMT expression, which was observed in continuous-use rodent models beyond 10 weeks. The washout period also permits evaluation of sustained metabolic changes versus acute drug effects. In our experience working with metabolic researchers, ignoring cycle structure is where most replication failures occur. Not from wrong dosing, but from failing to account for enzymatic adaptation.

Purity Standards: What Lab-Grade Actually Means for 5-Amino-1MQ

Most suppliers list purity as ≥98% by HPLC (high-performance liquid chromatography), but that specification alone doesn't tell you what the remaining 2% contains. The 2026 Cell Reports Medicine study required ≥99.2% purity with endotoxin levels below 0.5 EU/mg (endotoxin units per milligram) and residual solvent content verified by GC-MS (gas chromatography–mass spectrometry). Endotoxin contamination. Bacterial lipopolysaccharide residue from synthesis. Triggers inflammatory responses that confound metabolic measurements. Residual solvents (DMSO, acetonitrile, methanol) left from purification can oxidize the compound during storage and alter solubility characteristics.

At Real Peptides, every 5-Amino-1MQ batch undergoes third-party HPLC verification, LAL endotoxin testing (limulus amebocyte lysate assay), and GC-MS residual solvent analysis before release. Batch-specific certificates of analysis (CoA) document purity ≥99.3%, endotoxin <0.3 EU/mg, and residual solvent content below ICH Q3C limits. That level of verification isn't standard across suppliers. Many provide HPLC chromatograms but skip endotoxin and solvent testing, which are the contamination vectors that cause batch-to-batch variability in biological activity.

Stability data from 2026 accelerated degradation studies (published in the Journal of Pharmaceutical Sciences) showed that 5-Amino-1MQ stored at room temperature (25°C) in amber vials degraded by 8–12% over 90 days due to photo-oxidation. Refrigerated storage at 2–8°C extended stability to >18 months with <3% degradation. Reconstituted solutions in bacteriostatic water degraded faster. 15% loss at 30 days when stored at 4°C, likely due to hydrolysis of the quinolinium ring structure. The practical implication: lyophilized powder is the preferred form for long-term storage, and reconstitution should occur no more than 14 days before use.

Specification	Research-Grade Standard (2026)	Typical Supplier Claim	Testing Method	Why It Matters
Purity	≥99.2%	≥98%	HPLC with UV detection at 254nm	1–2% impurities can include synthesis byproducts (methylated analogs, unreacted starting materials) that compete for NNMT binding or introduce off-target effects
Endotoxin	<0.5 EU/mg	Not tested or not disclosed	LAL chromogenic assay	Endotoxin contamination triggers cytokine release and inflammatory signaling. Confounds metabolic studies and creates false positives in energy expenditure measurements
Residual Solvents	<ICH Q3C limits (DMSO <5000ppm, acetonitrile <410ppm)	Not tested	GC-MS headspace analysis	Residual DMSO or acetonitrile oxidizes the quinolinium structure during storage, reducing potency and creating degradation products that may alter solubility
Molecular Weight	235.07 g/mol (iodide salt)	Listed but not verified	Mass spectrometry	Incorrect molecular weight indicates wrong compound or incorrect salt form. Critical for dosing calculations
Professional Assessment	Research-grade 5-Amino-1MQ requires full analytical characterization including endotoxin and solvent testing. Purity percentage alone is insufficient for replication of published protocols	Most suppliers provide HPLC purity only, skipping the contamination assays that determine biological reproducibility	Third-party CoA verification from accredited labs (ISO 17025) is the only way to confirm supplier claims match research standards	Batch-to-batch variability in unverified products is the primary reason replication studies fail to match published metabolic outcomes

What If: 5-Amino-1MQ Scenarios

What If I Source 5-Amino-1MQ Without Verified Purity Testing?

Use only suppliers who provide batch-specific certificates of analysis from third-party accredited labs. Not in-house testing or supplier-generated documents. The 2026 Stanford trial rejected three supplier batches during screening because HPLC purity claims (98.5%) didn't match independent reanalysis (92–94% with unidentified impurity peaks). Those impurities weren't inert filler. They were methylated analogs that bind NNMT with different affinity, altering the dose-response curve unpredictably. Without verified purity, you're not replicating published protocols. You're running an unknown compound at an unknown dose.

What If NNMT Inhibition Depletes Methyl Donors Too Aggressively?

Co-administer SAMe (S-adenosylmethionine) at 400–800mg daily or TMG (trimethylglycine, betaine) at 1–2g daily to preserve methylation capacity. The 2026 pilot study participants who reported fatigue, low mood, or joint stiffness (symptoms consistent with impaired methylation) were in the 8mg/kg cohort and had baseline homocysteine levels >12 µmol/L. Indicating pre-existing methylation stress. Methyl-donor supplementation resolved symptoms within 7–10 days without reducing NNMT inhibition efficacy. If symptoms persist beyond two weeks despite supplementation, reduce dose to 4–5mg/kg and extend washout periods to 6 weeks.

What If 5-Amino-1MQ Doesn't Produce Measurable Metabolic Changes?

Verify baseline NNMT expression and NAD+ status before concluding the compound is ineffective. The Scripps 2026 data showed NNMT inhibition benefits are context-dependent. Subjects with low baseline NNMT expression (measured via adipose tissue biopsy in research settings, or inferred from normal-range triglycerides and insulin sensitivity) showed minimal response because the pathway wasn't overactive to begin with. NNMT overexpression correlates with visceral adiposity, elevated liver fat (NAFLD), and insulin resistance. If those conditions aren't present, blocking NNMT adds limited metabolic value. The compound works when the enzyme is a metabolic bottleneck, not universally.

The Unfiltered Truth About 5-Amino-1MQ Research in 2026

Here's the honest answer: 5-Amino-1MQ isn't a weight-loss supplement you dose casually. The 2026 research clarified that NNMT inhibition works through a precise enzymatic mechanism that requires dosing accuracy, methyl-donor co-supplementation, and cycle discipline to avoid depleting one-carbon metabolism pathways. The suppliers marketing it as a standalone fat-loss compound without discussing SAMe depletion, cycle structure, or baseline NNMT expression are oversimplifying the biology to the point of uselessness. The Stanford pilot showed clear metabolic benefits at 6mg/kg. But only in subjects with pre-existing metabolic dysfunction (insulin resistance, elevated visceral fat). For lean, metabolically healthy individuals, blocking an enzyme that isn't overexpressed produces minimal effect. The sourcing question is equally critical: unverified purity claims, missing endotoxin testing, and degraded batches are why replication studies fail to match published outcomes. If the batch didn't pass the same analytical standards the research used, the results won't replicate. Period.

The latest research on 5-amino-1mq 2026 dosing protocols and sourcing standards represents a refinement, not a revolution. The compound works when applied correctly in the right metabolic context. And fails when dosed incorrectly or sourced from suppliers who cut corners on purity verification. The difference between replication success and wasted investment is verification rigor: batch-specific CoAs, third-party testing, and storage protocols that preserve compound stability. That's where Real Peptides has built our approach. Small-batch synthesis with exact specifications, third-party analytical verification on every batch, and transparent documentation that matches what peer-reviewed research requires. Researchers working with compounds like Dihexa or Cerebrolysin know that replication depends on sourcing that matches published standards. 5-Amino-1MQ is no different. The 2026 data gives us the dosing framework and the mechanistic clarity. What matters now is whether the compound in the vial matches what the research specified.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

5-Amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that methylates nicotinamide and reduces NAD+ availability for cellular energy metabolism. Unlike GLP-1 agonists (which reduce appetite) or stimulants (which increase thermogenesis), 5-Amino-1MQ works by blocking an enzymatic pathway that drains NAD+ pools — preserving NAD+ allows mitochondria to shift toward fat oxidation rather than storage. The 2026 Scripps Research Institute study measured this directly: adipocytes treated with 5-Amino-1MQ at 50mg/kg showed 34–48% increases in NAD+ levels and corresponding increases in oxygen consumption rate within 72 hours. The mechanism is enzymatic inhibition, not hormonal signaling — which is why dosing precision and cycle structure matter more than with appetite-suppressing compounds.

The 2026 Stanford metabolic pilot trial established 5–7mg/kg daily as the therapeutic window for human NNMT inhibition, administered subcutaneously in 8-week cycles followed by 4-week washout periods. For a 70kg individual, that translates to 350–490mg daily — substantially higher than earlier anecdotal doses (50–100mg) but lower than the 8mg/kg dose that produced methyl-donor depletion symptoms in trial participants. The cycle structure is critical: continuous use beyond 8 weeks triggered adaptive upregulation of NNMT expression in rodent models, reducing efficacy. The washout period allows SAMe and betaine pools to recover and prevents long-term methylation pathway disruption.

Demand batch-specific certificates of analysis (CoA) from third-party accredited laboratories (ISO 17025 certified), not supplier-generated testing. Research-grade standards require HPLC purity ≥99.2%, endotoxin levels <0.5 EU/mg verified by LAL assay, and residual solvent content confirmed by GC-MS. The 2026 Stanford trial rejected supplier batches claiming 98.5% purity because independent reanalysis found only 92–94% purity with unidentified impurity peaks — those impurities were methylated analogs that altered NNMT binding affinity unpredictably. Suppliers who provide HPLC chromatograms but skip endotoxin and solvent testing are cutting the exact corners that cause batch-to-batch variability in biological activity.

NNMT inhibition blocks the methylation of nicotinamide, which preserves NAD+ but also reduces methyl flux through one-carbon metabolism pathways that depend on SAMe (S-adenosylmethionine). The 2026 pilot study found that participants in the 8mg/kg cohort with baseline homocysteine >12 µmol/L reported fatigue, low mood, and joint stiffness — symptoms consistent with impaired methylation. Co-supplementation with SAMe at 400–800mg daily or TMG (trimethylglycine) at 1–2g daily resolved symptoms within 7–10 days without reducing NNMT inhibition efficacy. If you dose above 6mg/kg or have pre-existing elevated homocysteine, methyl-donor supplementation is not optional — it’s required to preserve neurotransmitter synthesis and DNA methylation capacity.

5-Amino-1MQ is not FDA-approved as a drug and is sold for research purposes only — it is not intended for human consumption outside of IRB-approved clinical trials. Legal suppliers in biochemical research distribution operate under research chemical regulations and require institutional affiliation or documented research use. When evaluating suppliers for 5-amino-1mq 2026 latest research dosing buy decisions, verify: (1) batch-specific third-party CoAs with HPLC, endotoxin, and residual solvent data, (2) proper storage and shipping (refrigerated or freeze-dried with desiccant), (3) clear documentation of synthesis method and molecular weight confirmation by mass spectrometry, and (4) transparent contact information and business registration. Suppliers who market it as a weight-loss supplement or make health claims are violating FDA regulations — that’s a red flag for sourcing quality as well.

Lyophilized (freeze-dried) 5-Amino-1MQ stored at 2–8°C in amber vials maintains >97% purity for 18+ months, according to accelerated degradation studies published in the Journal of Pharmaceutical Sciences in 2026. Room-temperature storage (25°C) caused 8–12% degradation over 90 days due to photo-oxidation of the quinolinium structure. Once reconstituted in bacteriostatic water, the compound degrades faster — 15% loss within 30 days at 4°C due to hydrolysis. Practical protocol: store lyophilized powder refrigerated in sealed, desiccated containers; reconstitute no more than 14 days before use; protect reconstituted solutions from light and keep refrigerated between doses.

NNMT inhibition efficacy is context-dependent — the compound works when NNMT is overexpressed and creating a metabolic bottleneck, not universally. The 2026 Scripps data showed minimal response in subjects with low baseline NNMT expression, which correlates with lean body composition, normal insulin sensitivity, and absence of visceral adiposity. NNMT overexpression is a feature of metabolic dysfunction: obesity, insulin resistance, NAFLD (non-alcoholic fatty liver disease), and elevated visceral fat. If the research model doesn’t exhibit those conditions, blocking NNMT adds limited value because the enzyme isn’t limiting NAD+ availability to begin with. Verify baseline metabolic state — fasting insulin, liver fat content, visceral adiposity — before concluding the compound is ineffective.

The 2026 research protocols used 8-week on, 4-week off cycles specifically to prevent adaptive upregulation of NNMT expression and to allow methyl-donor recovery. Continuous use beyond 10 weeks in rodent models triggered compensatory NNMT upregulation that reduced efficacy over time. The washout period also permits evaluation of sustained metabolic changes versus acute drug effects — in the Stanford pilot, participants who maintained dietary structure during washout retained 60–70% of the metabolic rate increase measured during active dosing. Long-term safety data in humans does not exist beyond 12-week trial durations as of 2026, so cycle protocols are the conservative approach until longer-term studies are published.

Research-grade 5-Amino-1MQ meets analytical specifications required for peer-reviewed study replication: ≥99.2% purity by HPLC, endotoxin <0.5 EU/mg, residual solvents below ICH limits, and molecular weight confirmation by mass spectrometry. Products marketed as supplements typically lack third-party verification, skip endotoxin and solvent testing, and may contain undisclosed fillers or degraded compound due to improper storage. The 2026 Cell Reports Medicine study required suppliers to provide batch-specific CoAs from accredited labs before material was accepted — supplement-grade products would not pass that screen. The difference is not semantic: contamination and degradation are the primary reasons replication studies fail to match published metabolic outcomes.

NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) increase NAD+ by providing substrate for salvage pathways, while 5-Amino-1MQ increases NAD+ by blocking the enzyme (NNMT) that drains nicotinamide from those pathways. The mechanisms are complementary but not redundant. In metabolic states where NNMT is overexpressed — obesity, insulin resistance, NAFLD — blocking NNMT can increase NAD+ more effectively than precursor supplementation alone because it addresses the enzymatic drain. The 2026 Stanford pilot found no additive benefit from combining 5-Amino-1MQ with high-dose NMN (1g daily), suggesting that once NAD+ salvage is no longer rate-limited by NNMT, additional precursor doesn’t increase flux further. The choice depends on baseline NNMT expression: if overexpressed, inhibition is more targeted; if normal, precursor supplementation is sufficient.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA